Cytosorbents (CTSO) Stock Price, News & Analysis

Company Overview

Cytosorbents Corporation, founded in 2011 and headquartered in Princeton, New Jersey, is a medical device company focused on critical care and extracorporeal blood purification. The company’s flagship product, CytoSorb, is a hemoadsorption cartridge designed to remove excessive inflammatory mediators such as cytokines, bilirubin and myoglobin from a patient’s blood. By targeting the molecular drivers of hyperinflammation, CytoSorb is intended to stabilize patients undergoing septic shock, cardiac surgery, trauma and organ failure.

CytoSorb has secured regulatory clearance in Europe (CE mark) and is available in more than 65 countries, with a growing presence in Asia, the Middle East and Latin America. In the United States, the device received Emergency Use Authorization from the U.S. Food and Drug Administration for treatment of critically ill COVID-19 patients exhibiting a cytokine storm. Clinicians integrate CytoSorb into standard extracorporeal circuits such as continuous renal replacement therapy (CRRT) and cardiopulmonary bypass to optimize blood purification protocols in intensive care units.

Beyond its core sorbent technology, Cytosorbents is advancing a pipeline of next-generation products aimed at drug overdose management and vaccine adjuvant development. The company’s R&D efforts leverage proprietary polymer bead platforms to broaden the applications of hemoadsorption in pharmaceutical safety and immunotherapy. With a global sales and distribution network and strategic partnerships in key markets, Cytosorbents continues to expand clinical evidence to support broader adoption of its blood purification solutions.

Key Stats

• Today's Range: $0.38 to $0.40
• 50-Day Range: $0.35 to $0.52
• 52-Week Range: $0.35 to $1.19
• Volume: 51,679 shs
• Average Volume: 62,960 shs
• Market Capitalization: $23.70 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $5.38
• Consensus Rating: Hold

Cytosorbents Stock Analysis - MarketRank™

Cytosorbents scored higher than 35% of companies evaluated by MarketBeat, and ranked 733rd out of 912 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

Cytosorbents has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 1 sell rating.

Upside Potential

Cytosorbents has a consensus price target of $5.38, representing about 1,325.0% upside from its current price of $0.38.

Amount of Analyst Coverage

Cytosorbents has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Cytosorbents is -1.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cytosorbents is -1.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Cytosorbents has a P/B Ratio of 4.19. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

3.70% of the float of Cytosorbents has been sold short.

Short Interest Ratio / Days to Cover

Cytosorbents has a short interest ratio ("days to cover") of 38.34, which indicates bearish sentiment.

Change versus previous month

Short interest in Cytosorbents has recently increased by 1.12%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cytosorbents does not currently pay a dividend.

Dividend Growth

Cytosorbents does not have a long track record of dividend growth.

News and Social Media

• Score: 0.9 / 5
• News Sentiment: -0.54

News Sentiment

Cytosorbents has a news sentiment score of -0.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 10 news articles for Cytosorbents this week, compared to 3 articles on an average week.

Search Interest

Only 3 people have searched for CTSO on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.

Company Ownership

• Score: 3.5 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $104,898.00 in company stock, which represents 0.4425% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Cytosorbents insiders have bought more of their company's stock than they have sold. Specifically, they have bought $104,898.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

7.80% of the stock of Cytosorbents is held by insiders.

Percentage Held by Institutions

32.87% of the stock of Cytosorbents is held by institutions.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 8/17/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NASDAQ:CTSO
• CIK: 1175151
• Web: www.cytosorbents.com
• Phone: (732) 329-8885
• Fax: 732-329-8650
• Employees: 220
• Year Founded: 2002

Price Target and Rating

• Average Price Target for Cytosorbents: $5.38
• High Price Target: $10.00
• Low Price Target: $0.75
• Potential Upside/Downside: +1,325.0%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.29)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$8.20 million
• Net Margins: -48.94%
• Pretax Margin: -50.01%
• Return on Equity: -431.65%
• Return on Assets: -41.94%

Debt

• Debt-to-Equity Ratio: 4.70
• Current Ratio: 0.66
• Quick Ratio: 0.50

Sales & Book Value

• Annual Sales: $37.06 million
• Price / Sales: 0.64
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.09 per share
• Price / Book: 4.19

Miscellaneous

• Outstanding Shares: 62,840,000
• Free Float: 57,941,000
• Market Cap: $23.70 million
• Optionable: Optionable
• Beta: 1.39